Literature DB >> 26395582

Psilocybin, psychological distress, and suicidality.

Peter S Hendricks1, Matthew W Johnson2, Roland R Griffiths2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26395582      PMCID： PMC4721603          DOI： 10.1177/0269881115598338

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN： 0269-8811            Impact factor:   4.153


× No keyword cloud information.
  15 in total

Review 1.  Comparison of acute lethal toxicity of commonly abused psychoactive substances.

Authors:  Robert S Gable
Journal:  Addiction       Date:  2004-06       Impact factor: 6.526

2.  Linking "big" personality traits to anxiety, depressive, and substance use disorders: a meta-analysis.

Authors:  Roman Kotov; Wakiza Gamez; Frank Schmidt; David Watson
Journal:  Psychol Bull       Date:  2010-09       Impact factor: 17.737

3.  The link between use of psychedelic drugs and mental health problems.

Authors:  Ragnar Nesvåg; Jørgen G Bramness; Eivind Ystrom; Teri Suzanne Krebs; Pål-Ørjan Johansen
Journal:  J Psychopharmacol       Date:  2015-09       Impact factor: 4.153

Review 4.  Common liability to addiction and "gateway hypothesis": theoretical, empirical and evolutionary perspective.

Authors:  Michael M Vanyukov; Ralph E Tarter; Galina P Kirillova; Levent Kirisci; Maureen D Reynolds; Mary Jeanne Kreek; Kevin P Conway; Brion S Maher; William G Iacono; Laura Bierut; Michael C Neale; Duncan B Clark; Ty A Ridenour
Journal:  Drug Alcohol Depend       Date:  2012-01-18       Impact factor: 4.492

Review 5.  Reassessing the marijuana gateway effect.

Authors:  Andrew R Morral; Daniel F McCaffrey; Susan M Paddock
Journal:  Addiction       Date:  2002-12       Impact factor: 6.526

6.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

Authors:  Charles S Grob; Alicia L Danforth; Gurpreet S Chopra; Marycie Hagerty; Charles R McKay; Adam L Halberstadt; George R Greer
Journal:  Arch Gen Psychiatry       Date:  2010-09-06

Review 7.  Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically.

Authors:  R S Gable
Journal:  Am J Drug Alcohol Abuse       Date:  1993       Impact factor: 3.829

8.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Mary P Cosimano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2014-09-11       Impact factor: 4.153

9.  Overadjustment bias and unnecessary adjustment in epidemiologic studies.

Authors:  Enrique F Schisterman; Stephen R Cole; Robert W Platt
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

10.  Effects of Schedule I drug laws on neuroscience research and treatment innovation.

Authors:  David J Nutt; Leslie A King; David E Nichols
Journal:  Nat Rev Neurosci       Date:  2013-06-12       Impact factor: 34.870
View more
  18 in total

1.  Clinical potential of psilocybin as a treatment for mental health conditions.

Authors:  Jeremy Daniel; Margaret Haberman
Journal:  Ment Health Clin       Date:  2018-03-23

Review 2.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Authors:  Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

Review 3.  Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.

Authors:  Sam G Moreton; Luke Szalla; Rachel E Menzies; Andrew F Arena
Journal:  Psychopharmacology (Berl)       Date:  2019-11-29       Impact factor: 4.530

4.  Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults.

Authors:  Kevin H Yang; Benjamin H Han; Joseph J Palamar
Journal:  Addict Behav       Date:  2022-04-28       Impact factor: 4.591

5.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

6.  Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.

Authors:  Stephen Ross; Gabrielle Agin-Liebes; Sharon Lo; Richard J Zeifman; Leila Ghazal; Julia Benville; Silvia Franco Corso; Christian Bjerre Real; Jeffrey Guss; Anthony Bossis; Sarah E Mennenga
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-18

Review 7.  On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.

Authors:  Richard J Zeifman; Nikhita Singhal; Leah Breslow; Cory R Weissman
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-11

8.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

Review 9.  The Therapeutic Potential of Psilocybin.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Henkel Valentine; Justin Grant; Amza Ali; Wilfred Ngwa; Lorenzo Gordon
Journal:  Molecules       Date:  2021-05-15       Impact factor: 4.411

10.  Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.

Authors:  Taylor Lyons; Robin L Carhart-Harris
Journal:  J Psychopharmacol       Date:  2018-01-17       Impact factor: 4.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.